As a new month begins, it could be worthwhile for investors to look back at the previous month and have look at some of the stocks which climbed considerably. One of the stocks that could be worth tracking is that of Amarin Corporation (NASDAQ: AMRN), which recorded gains of as big as 50% during January.
That being said, it should be noted that the company received a considerable boost last week and hence, Amarin could well be in focus among investors this week.
Last week it emerged that the company got a positive recommendation with regards to the marketing application of its product icosapent ethyl from the Committee for Medicinal Products for Human Use.
The product in question is meant for reducing the risk of cardiovascular events in patients who are classified as high risk. It has also emerged that the product in question is going to be marketed with the name VAZKEPA. Considering this development, it could be worthwhile to put the Amarin stock in the watch lists.